1 November 1998 in The Journal of Infectious Diseases
The C2–V3 region of the human immunodeficiency virus (HIV)-1 env was determined from 15 northern Thailand seroconverters between 1993 and 1995. Similar sequences were also determined from 18 seroconverting injection drug users in Baltimore. All seroconverters from northern Thailand were infected with subtype E HIV-1 on the basis of env sequences. Intersubject viral DNA distances increased from 2.3% in asymptomatic HIV-1—infected subjects characterized between 1990 and 1992 to 7.8% in these more recent seroconverters from Thailand. On the other hand, sequences from 18 seroconverters from Baltimore had a mean intersubject distance of 13.2%. The genetic diversity within HIV-1 subtype E in seroconverters in Thailand has increased significantly but is still less than that observed in HIV-1 from seroconverters in the United States, where the epidemic of HIV-1 infection is more mature. These results suggest that continued monitoring of the molecular epidemiology of HIV-1 infection in Thailand will be important for HIV vaccine development and evaluation.
21 October 2025 in Open Forum Infectious Diseases
Background: People with diagnosed HIV (PWDH) live longer but have increased co-morbidities than peers without HIV and premature ageing. In 2021, 54% of United States PWDH were aged ≥50 years. PWDH age distribution projections beyond 2030 are needed to plan future HIV and ageing care. Methods: Our life table-based model used 2020–2021 Centers for Disease Control and Prevention National HIV Surveillance System data to project PWDH age distributions from 2021–2040 across three modeled scenarios, varying annual percentage change (APC) in HIV diagnoses (new infections proxy) and PWDH mortality rate. Results: The median age of PWDH increased from 51 years (2021) to 55–60 years (2040) when diagnoses decreased. Numbers of older PWDH increased across racial/ethnic groups and regions, regardless of decreasing or increasing diagnoses or reducing mortality. Reducing diagnoses 90% by 2040 with reduced mortality estimated 75% (695 912) of PWDH would be aged ≥50 years, 42% (388 639) aged ≥65 years, and 20% (190 600) aged ≥75 years. Extending −3% APC reductions in diagnoses projected 64% (670 977) aged ≥50 years, 33% (350 025) aged ≥65 years, and 16% (168 139) aged ≥75 years. Modestly increasing diagnoses projected 53% (761 194) aged ≥50 years, 26% (371 244) aged ≥65 years, and 12% (171 233) aged ≥75 years. Across scenarios, the number of PWDH aged ≥50, ≥65, and ≥75 years, respectively, increased 18%–34%, 144%–171%, and 565%–654%. Conclusions: By 2040, the estimated number of older PWDH will increase substantially, regardless of decreasing or increasing HIV diagnoses. The healthcare sector must prepare now to ensure future ageing-related care needs of PWDH are met.
16 August 2024 in medRxiv
Background: Despite progress in HIV prevention and treatment, resulting in overall incidence reductions in the United States, large racial/ethnic (r/e) disparities in HIV incidence remain due to stigma, discrimination, racism, poverty, and other social and structural factors. Setting: We used the HIV Optimization and Prevention Economics (HOPE) model to analyze which intervention strategies provide the most effective path towards eliminating r/e disparities in HIV incidence. Methods: We considered four intervention scenarios for 2023-2035, which focused on eliminating r/e disparities by 2027 in the HIV care continuum only, HIV prevention services only, both continuum and prevention services, and a final scenario where prevention and care levels for Black and Hispanic/Latino were set to maximum feasible levels. The primary outcome is the incidence-rate-ratio (IRR) for Black and Hispanic/Latino populations compared to Other populations (of whom 89% are White) with the goal of IRRs ≤ 1 by 2035. Results: All scenarios reduced IRRs but only Maximum Feasible eliminated HIV incidence disparities by 2035, with respective IRRs of 0.9 and 1.1 among the Black and Hispanic/Latino populations, compared to 6.5 and 4.1 in the baseline scenario. Continuum-only was more effective at reducing disparities (2035 IRRs of 4.7 for Black and 3.1 for Hispanic/Latino populations) than Prevention-only (6.1 and 3.7 respectively). Conclusions: With no prioritized changes, our simulation showed that r/e disparities in HIV incidence persist through 2035. Elimination of r/e incidence disparities by 2035 is only possible if maximum HIV prevention and care levels for Black and Hispanic/Latino populations can be realized by 2027.